Explore Arvinas through 10+ example sentences from English. Ideal for language learners, writers and word enthusiasts.
Arvinas in a sentence
Using Arvinas
- In the example corpus, arvinas often appears in combinations such as: arvinas by, of arvinas, in arvinas.
Context around Arvinas
- Average sentence length in these examples: 17.8 words
- Position in the sentence: 2 start, 10 middle, 0 end
- Sentence types: 12 statements, 0 questions, 0 exclamations
Corpus analysis for Arvinas
- In this selection, "arvinas" usually appears in the middle of the sentence. The average example has 17.8 words, and this corpus slice is mostly made up of statements.
- Around the word, inc stand out and add context to how "arvinas" is used.
- Recognizable usage signals include arvinas inc a and coverage on arvinas in a. That gives this page its own corpus information beyond isolated example sentences.
- By corpus frequency, "arvinas" sits close to words such as aami, aat and abada, which helps place it inside the broader word index.
Example types with arvinas
The same corpus examples are grouped by length and sentence type, making it easier to see the contexts in which the word appears:
Stephens started coverage on Arvinas in a report on Monday, November 18th. (12 words)
BlackRock Inc. increased its stake in Arvinas by 0.9% during the 3rd quarter. (14 words)
This is a breakdown of recent recommendations for Arvinas and its rivals, as reported by MarketBeat. (16 words)
HC Wainwright reissued a “buy” rating and issued a $87.00 price objective on shares of Arvinas in a research note on Thursday. (23 words)
Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. (21 words)
Finally, Price T Rowe Associates Inc. MD grew its holdings in Arvinas by 8.6% during the 4th quarter. (19 words)
Example sentences (12)
Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
BlackRock Inc. increased its stake in Arvinas by 0.9% during the 3rd quarter.
EcoR1 Capital LLC raised its stake in shares of Arvinas by 19.0% during the first quarter.
Finally, Price T Rowe Associates Inc. MD grew its holdings in Arvinas by 8.6% during the 4th quarter.
Pathstone Family Office LLC purchased a new stake in Arvinas in the fourth quarter valued at approximately $207,000.
Tower Research Capital LLC TRC grew its stake in shares of Arvinas by 57.4% in the first quarter.
HC Wainwright reissued a “buy” rating and issued a $87.00 price objective on shares of Arvinas in a research note on Thursday.
Opaleye Management Inc. increased its stake in shares of Arvinas by 25.1% during the first quarter.
Principal Financial Group Inc. raised its holdings in shares of Arvinas by 3.8% in the first quarter.
Stephens started coverage on Arvinas in a report on Monday, November 18th.
Arvinas, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
This is a breakdown of recent recommendations for Arvinas and its rivals, as reported by MarketBeat.
Common combinations with arvinas
These word pairs occur most frequently in English texts:
- arvinas by 6×
- of arvinas 5×
- in arvinas 3×
- arvinas in 3×
- arvinas inc 2×